Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in pediatric heterozygous familial hypercholesterolemia
2014-002277-11Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Evolocumab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Percent change from baseline to week 24 in LDL-C. Started May 2015; status: completed.
02
Drugs
evolocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2014-002277-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002277-11.